ARTV · Artiva Biotherapeutics, Inc.
$10.00
-0.53 (-5.03%)
At close · Jul 29
Market Cap
$260.27M
Shares
24.72M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$10.53
Open$10.30
Day$9.97–10.64
52W$2.22–14.53
Avg vol 30d534K
Short int1.7M · 7.0% float · 3.8d
Short vol55%
Last earningsJun 8, 2026
DataJul 2024–Jul 2026
Filing10-Q · May 8
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 8, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+65%
above
Price vs 50-day avg
+19%
above
RSI (14)
60
neutral
MACD trend
Positive
52-week position
68%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+10%
trailing
6-month return
+154%
trailing
YTD return
+145%
this year
Relative strength
+147%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $9 › 200d $6 — 50d above 200d
Institutional flow
Accumulating
3 of 40 funds reported for Jun 30 · net +79.8K sh shares · +2 new
Insider flow
Accumulating
Net +$108.1M over 90 days · 71% sells
Short interest
Rising
6.98% of float · ▲ +28.7% MoM · 3.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
40 holders — mid 1-yr range
Squeeze score
76
high risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+41%
Y/Y
Free cash flow
$-79.3M
Balance sheet
$26.7M
net cash
Quant / Vol
risk profile
Volatility
186%
annualized · 1-yr
Max drawdown
−51%
past year
ATR
8.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+65%
Bullish
Price vs 50-day avg
+19%
Bullish
RSI (14)
60
Neutral
MACD trend
Positive
Bullish
52-week position
68%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $9 › 200d $6 — 50d above 200d
Institutional flow
Accumulating
3 of 40 funds reported for Jun 30 · net +79.8K sh shares · +2 new
Insider flow
Accumulating
Net +$108.1M over 90 days · 71% sells
Short interest
Rising
6.98% of float · ▲ +28.7% MoM · 3.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
40 holders — mid 1-yr range
Price context
position in its 52-week range
52-wk low $2
Now $11 · 68%
52-wk high $15
vs 200-day avg +65%
vs 50-day avg +19%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ARTV
this stock
Artiva Biotherapeutics, Inc.
|
$260.27M | +145.5% | -99.3% | — | 7.0% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +8.8% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ARTV | +5.3% | +9.9% | +154.4% | +8.6% | +145.5% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | +6.3% | +9.9% | +146.9% | +9.4% | +136.8% |